Perrigo ANDA Approval Brings New Options To Generic Mucinex DM Maximum Strength Portfolio
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Perrigo's first OTC drug approved in 2018 is extended-relief guaifenesin 1,200 mg and dextromethorphan 60 mg tablets, planned for launch under its own store brand, Goodsense, as well as distribution for retailer and private label brands. It already distributes the product for store and private label brands through an agreement with Teva.
You may also be interested in...
Perrigo Gains US Approval For OTC Guaifenesin/Pseudoephedrine Manufacturing
Predominant US OTC private label/store brand provider plans commercialize products in second half. Firm has yet to set date to release 2021 full-year and fourth-quarter results.
Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division
As new CEO Uwe Röhrhoff plans a "value creation" analysis, the improving Rx business growth could be essential for company because US competition from smaller, online brands is increasing in the OTC drug space and its sales of its consumer health products in Europe have yet to reach expectations.
Perrigo Taps CEO With Global Operations Expertise At Pharma Packaging Firm
Perrigo named German packaging firm executive Uwe Rohrhoff as CEO, replacing John Hendrickson, effective Jan. 15. The former head of Gerresheimer will bring experience leading a global business that included 36 manufacturing facilities across 14 countries and sales of $1.7bn.